Heparin: profile and news

Cut risks of killer blood clots  07 Mar 2006
...their risk of DVT. Fortunately, a variety of drugs exist, such as heparin, Lovenox, Arixtra and Coumadin. DVT is facetiously called ... - El Paso Times,

PolyMedix Appoints Edward Smith Vice President Finance and CFO  07 Mar 2006
...disorders, the Company is developing is an anticoagulant antagonist, a small molecule compound which can reverse the activity of both heparin and low molecular ... - Business Wire (press release),

The Pulse of Heart-Drug Research  Mar 5, 2006
The Medicines Company (MDCO) completed this 13,800 patient study in December, comparing its drug Angiomax against heparin, a generic, for patients with acute ... - BusinessWeek

Acquired haemophilia in urticarial vasculitis revealed by ...  Feb 28, 2006
She was treated with low molecular weight heparin and was asked to return the next day for Doppler studies. However, her general condition proceeded to worsen. ... - Journal of the Royal Society of Medicine

Low-Molecular-Weight Heparin More Effective in Ischemic Stroke ...  Feb 22, 2006
KISSIMMEE, FL -- February 22, 2006 -- The effects of low-molecular-weight heparin (LMWH) in acute ischemic stroke differ depending on whether or not the ... - DG News

Vegan? Sorry, We Have Porcine Heparin on the Menu!  Feb 21, 2006
We recently encountered a patient who was a strict vegan and refused the use of heparin for cardiac surgery because of its porcine origin. ... - Anesthesia & Analgesia (subscription),

Alternative method to produce heparin  Feb 7, 2006
Heparin is a complex carbohydrate used to stop or prevent blood from clotting during medical procedures and treatments such as kidney dialysis, heart bypass ... - News-Medical.net,

Synthetic Heparin may replace current drug  Feb 6, 2006
Rensselaer Polytechnic Institute and University of North Carolina-Chapel Hill scientists have found a new way to make the anti-blood clotting drug Heparin. ... - Webindia123,

New way to produce Heparin discovered through RPI collaboration  Feb 7, 2006
...in Troy, NY, and at the University of North Carolina in Chapel Hill have collaborated on the discovery of a new way to produce the drug heparin, which is used ... - Albany Business Review,

What ‘They’ Don’t Want You to Know  Mar 3, 2006
And they compared it to the drug Heparin. And this research showed that vitamin E worked as good or better than the drug Heparin. ... - Skeptical Inquirer

Patient Safety Authority Marks Patient Safety Awareness Week March ...  Mar 4, 2006
When the nurse mentioned [the drug] Heparin, the patient's spouse spoke up and said that the patient was allergic to Heparin. The ... - Medical News Today (press release),

HOW DID OUR DAD DIE?  Mar 3, 2006
The 57-year-old had been given a dose of anti blood-clotting agent heparin - one-third stronger than recommended - on top of another blood-thinning drug ... - Bristol Evening Post,

The Doctor's World Sharon, Gravely Ill, Invited the Public Inside  Feb 27, 2006
He was given an anticoagulant known as low molecular weight heparin to help prevent a clot, causing another stroke. Also, he was to undergo a procedure on Jan. ... - New York Times,

(PRN) Encysive Pharmaceuticals Announces Retirement of Frank C. ...  Mar 3, 2006
We have successfully developed one FDA-approved drug, Argatroban, for the treatment of heparin-induced thrombocytopenia that is marketed by GlaxoSmithKline. ... - Houston Chronicle,

Medical Edge: Brace may help osteoporosis patient  Mar 4, 2006
Anticonvulsants, thyroid medications, immunosuppressants given after organ transplant, diuretics and blood thinners such as heparin can contribute to bone loss ... - Bryan College Station Eagle,

Researcher looks for more targeted way to deliver cancer drugs  Feb 21, 2006
Yang's work on the targeted drug delivery system is connected to his research on new ways to neutralize the anticoagulant Heparin. ... - U of M News Service (press release),

Liquidating a lethal blood clot  Feb 6, 2006
...clotting. He was prescribed heparin, but after two weeks his blood had not responded properly and he was experiencing chest pain. ... - Stuff.co.nz,

RPI aids blood-clot prevention  Feb 7, 2006
...at Rensselaer Polytechnic Institute and the University of North Carolina at Chapel Hill have discovered an alternative way to produce heparin, a drug commonly ... - Albany Times Union,

New Oral Anticoagulants Show Promise  Feb 14, 2006
The anticoagulant drugs warfarin and low-molecular-weight heparin, currently given to such patients to prevent and treat thromboembolic events, target ... - Journal of American Medical Association (subscription),

PolyMedix Raises $21 Million in Equity Financing; Company Will ...  Feb 22, 2006
These funds will be used to advance the first two drug candidates, an antibiotic and a heparin antagonist into human clinical trials in 2007. ... - Genetic Engineering News,

change it from life-threatening to  Feb 26, 2006
A drug called low molecular weight heparin has been used to treat thromboembolism for moe than 20 years and there is evidence it also has an anti-cancer effect ... - ic Wales,

Complete occlusion of the left main coronary artery complicated by ...  Feb 28, 2006
Thrombolysis and low molecular weight heparin were effective and the patient did well during subsequent hospitalisation period. ... - HeartZine,

Defending Human Embryonic Life - Essay  Feb 27, 2006
One can certainly imagine medical circumstances such as the comatose patient with heparin induced thrombocytosis and thrombosis who has lost all 4 extremities ... - Catholic Online,

Nuvelo Reports 2005 Fourth Quarter and Year End Results and ...  Feb 27, 2006
Initiation of a Phase 2 trial of alfimeprase in ischemic stroke in the second half of 2006; -- Completion of a Phase 2 rNAPc2 heparin replacement study in ... - Yahoo! News (press release)

Emisphere Technologies Announces Presentation and Webcast at the ...  Mar 1, 2006
Emisphere and its partners have advanced oral formulations or prototypes of salmon calcitonin, heparin, insulin, parathyroid hormone, human growth hormone and ... - PR Newswire (press release),

Biotie Therapies Oyj: Biotie therapies corp. revised outlook for ...  Mar 1, 2006
...development phase. BioTie is in discussions with new potential development partners to continue the recombinant heparin program. The ... - Kauppalehti (press release),

Cutting angioplasty risks  Feb 16, 2006
...could help prevent complications during or after their angioplasty, while others received far more than necessary of the blood-thinning drug heparin, or the ... - News-Medical.net,

'Pharmed' goats seek drug licence  Feb 22, 2006
..."Yes we do need to think about risk of disease transmission from animals, but we already use direct animal products such as heparin from pig tissue and leech ... - BBC News,

CardioTech International Reports Results for Third Quarter of ...  Feb 14, 2006
In September 2005, the Company received FDA approval for its heparin coated products for the cardiopulmonary bypass surgery market. ... - MSN Money

PolyMedix raises $21.2M, completes merger  Feb 22, 2006
The new funds will be used to advance the company's first two drug candidates, an antibiotic and a heparin-antagonist blood-clot medicine, into human clinical ... - Philadelphia Business Journal,

Arixtra Administered the Morning After Orthopedic Surgery ...  Feb 3, 2006
The efficacy and safety of Arixtra in patients with heparin induced thrombocytopenia type II has not been studied. Thrombocytopenia can occur with Arixtra. ... - DG News

Searching for Memory: The Brain, the Mind, and the Past  Feb 7, 2006
Heparin Prepared Synthetically Could Replace Animal-derived Drug (February 5, 2006) — Researchers at Rensselaer Polytechnic Institute and University of North ... - Science Daily (press release)

Parker & Waichman, LLP Files Suit Against Ortho-McNeil ...  Feb 24, 2006
...plaintiff was subsequently airlifted to Emory University Hospital and was admitted to the Neuro Intensive Care Unit where she underwent Heparin and Coumadin ... - Emediawire (press release),

Pivotal Study Published in British Medical Journal Reports ...  Feb 13, 2006
Heparin- induced thrombocytopenia (HIT) is not an expected side effect of ARIXTRA(R) as no causal relationship has been demonstrated to date. ... - PR Newswire (press release),

Encysive Pharmaceuticals Reports Fourth Quarter and Year End 2005 ...  Feb 13, 2006
We have successfully developed one FDA-approved drug, Argatroban, for the treatment of heparin-induced thrombocytopenia, which is marketed by GlaxoSmithKline. ... - MSN Money

Angioplasty Treatment Can Vary  Feb 11, 2006
At the seven comparison hospitals, the researchers found wide variation in the use of preventive medications, heparin and dye, and higher rates of some ... - International News Service,

Arixtra Effective and Well Tolerated in Acutely Ill Medical ...  Feb 14, 2006
Heparin-induced thrombocytopenia (HIT) is not an expected side effect of Arixtra as no causal relationship has been demonstrated to date. ... - DG News

Angioplasty Needs Guidance  Feb 14, 2006
Some patients received unnecessary supplies of the blood-thinning drug heparin, while others never received any of the numerous drugs that help prevent ... - Ivanhoe,

Blood clots in legs can be examined, prevented  Feb 9, 2006
...risk of PE. It consists of heparin which is usually given by IV followed by coumadin that is continued for several months. In some ... - SunHerald.com,

Activation of the coagulation system during coronary artery bypass ...  Feb 9, 2006
METHODS: Thirty-two patients were randomly assigned to on-pump or off-pump coronary artery bypass grafting. Heparin was given at the same dose. ... - The Journal of Thoracic and Cardiovascular Surgery

Thrombolytic Treatment Before Stenting Linked to Increased ...  Feb 14, 2006
Drugs used to facilitate the procedure included high-dose heparin, GP IIb/IIIa inhibitors, full-dose and reduced-dose thrombolytic drugs, and the combination ... - MedPage Today,

Superior vena cava replacement for lung cancer using a ...  Feb 14, 2006
...crossclamping technique. 2 Low doses of low-weight heparin were administered after surgery up until 1 month after discharge. All ... - The Journal of Thoracic and Cardiovascular Surgery

Biotechs? Use rubber gloves  Feb 3, 2006
..."Companies like Pharmaxis, ChemGenex (leukemia), Alchemia (synthetic heparin for thinning the blood), Ventracor (heart pump device) and Peplin (skin cancer ... - Australian,

International Teleradiology  Feb 15, 2006
A decade ago, the first patient might have been started on heparin therapy and scheduled for an early-morning ventilation–perfusion scan. ... - New England Journal of Medicine (subscription),

Plasmin Modulates Vascular Endothelial Growth Factor-A-Mediated ...  Feb 8, 2006
Plasmin-catalyzed cleavage of the vascular endothelial growth factor (VEGF)-A isoform VEGF165 results in loss of its carboxyl-terminal heparin-binding domain ... - Am J Pathology (subscription)

Patient care for Muslims a new need  Feb 16, 2006
...are also forbidden under Islam -- meaning some patients might need alternatives to common cough medicines that contain alcohol, or to heparin, a frequently ... - Boston Globe,

New Clinical Data Points to Promising Treatment for Ischemic ...  Feb 16, 2006
While many current treatment protocols advocate the use of Low Molecular Weight Heparin to arrest additional thrombus formation, this treatment does not ... - Yahoo! News (press release)

Unless really needed, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Lovenox Injection therapy. These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. If co-administration is essential, conduct close clinical and laboratory monitoring.

 


Chemical IUPAC Name
6-[5-acetylamino-4,6-dihydroxy-2-(sulfooxymethyl)tetrahydropyran-3-yl]oxy-3-[5-(6-carboxy-4,5-dihydroxy-3-sulfooxy-tetrahydropyran-2-yl)oxy-6-(hydroxymethyl)-3-sulfoamino-4-sulfooxy-tetrahydropyran-2-yl]oxy-4-hydroxy-5-sulfooxy-tetrahydropyran-2-carboxylicacid

Chemical Formula
(C26H40N2O36S5)n

Half Life
4.5 hours

Drug Type
Approved Drug

# Accession No
APRD00068

CAS Registry Number
9005-49-6